
THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:

1. Use of a phosphoramidate prodrug of troxacitabine with the formula:



wherein

a) X is H, Y is 2-propylpentyl and Z is H;

b) X is H, Y is (S)-pentan-2-yl and Z is H;

c) X is Br, Y is (S)-pentan-2-yl and Z is H;

d) X is H, Y is (R)-sec-butyl and Z is H;

e) X is H, Y is 2-ethylbutyl and Z is H;


f) X is cyclopropyl, Y is (S)-pentan-2-yl and Z is H; or

g) X is t-butyl, Y is (S)-pentan-2-yl and Z is H.

or a pharmaceutically acceptable salt thereof, in combination with a targeted therapeutic agent selected from sorafenib and regorafenib, in preparation of a medicament for the treatment of liver cancer or liver metastases.

2. The use according to claim 1, wherein the targeted therapeutic agent is sorafenib.

3. The use according to claim 1 or 2, wherein the phosphoramidate prodrug of troxacitabine has the stereochemistry:



4. The use according to claim 1 or 2, wherein X is Br, Y is (S)-pentan-2-yl and Z is H.

5. The use according to any one of the preceding claims, wherein the sorafenib and the phosphoramidate prodrug of troxacitabine are each to be administered daily (as QD, BID or TID) on the same day.

6. The use according to claim 5, wherein the sorafenib and the phosphoramidate prodrug of troxacitabine are to be co-delivered in a common, orally administered dosage unit.

7. The use according to claim 5, wherein sorafenib and the phosphoramidate prodrug of troxacitabine are to be administered as separate orally administered dosage units.

8. The use according to claim 7, wherein the dosage unit(s) of sorafenib and the dosage unit(s) of the phosphoramidate prodrug of troxacitabine are to be administered at least 6 hours apart on any given day.

9. The use according to any one of claims 1 to 4, wherein the sorafenib and the phosphoramidate prodrug of troxacitabine are to be alternately administered in monotherapy treatment cycles of 1-28 days, optionally interspersed with treatment-free periods of 1-28 days.

10. The use according to claim 9, wherein treatment commences with a sorafenib cycle.

11. The use according to any one of the preceding claims, wherein the liver cancer is HCC or intra-hepatic cholangiocarcinoma.

12. The use according to any one of claims 1 to 10, wherein the liver metastasis is derived from colorectal cancer.

13. The use according to any one of claims 1 to 10, wherein the liver metastasis is derived from breast cancer, esophageal cancer, lung cancer, melanoma, pancreatic cancer or stomach cancer.